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Previously, we observed a positive association of
prothrombin concentrations with thrombin generation
(fragment 1 + 2) and thrombin activity (fibrinopeptide A),
but no association with protein C activation peptide levels.
We further evaluated a potential beneficial effect of
increased prothrombin concentrations on activated protein
C generation by assessing the plasma concentration of
activated protein C in complex with protein C inhibitor
(APC–PCI). Blood samples were used from 195 family
members of a large French-Canadian kindred with type I
protein C deficiency due to a 3363C insertion in the protein
C gene. We utilized a new and highly sensitive assay for
measuring the concentration of APC–PCI complex as a
measure of the level of activation of protein C. Means of
the plasma concentrations of the APC–PCI complex were
compared among carriers and non-carriers of the
prothrombin G20210A mutation. Protein C activity levels
were positively associated with APC–PCI complex plasma
concentrations; however, APC–PCI complex levels were
not different for carriers of the prothrombin G20210A
mutation than for non-carriers. Thus, carriers of the
prothrombin G20210A mutation do not have increased
protein C activation despite the increased thrombin
generation resulting from the higher prothrombin
concentrations associated with the G20210A mutation.
Blood Coagul Fibrinolysis 15:573–576 & 2004 Lippincott
Williams & Wilkins.
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Introduction
Protein C is a vitamin K-dependent (molecular weight,
62 000) zymogen for a serine protease that downregu-
lates the hemostatic system through the proteolytic
inactivation of activated factor V (FVa) and activated
factor VIII. Protein C deficiency was first associated
with thrombophilia in 1981 [1]. Heterozygous defi-
ciency of protein C has a prevalence of one in 200 in
the general population [2]. The incidence of sympto-
matic disease in penetrant families is considerably
higher than in the general population [3–6]. The
apparent variable penetrance of thrombotic disease
among families with protein C deficiency has been
attributed to the co-segregation of additional risk
factors. Two likely candidates are the highly prevalent
risk factors for thromboembolic disease, factor V Lei-
den and the prothrombin G20210A polymorphism [7,8].
Since 1985, we have studied a large kindred of French-
Canadian descent with an eight-fold increased risk of
venous thrombosis and early onset of disease, asso-
ciated with a 3363C insertion mutation in the protein C
gene [3]. Segregation analysis suggested that the in-
creased risk of thrombosis found in this kindred
resulted from the interaction between the protein C
3363C insertion and another unknown genetic defect
[9]. Currently, we have identified 787 family members,
of whom 450 have been tested for the protein C 3363C
insertion. Factor V Leiden was found in only four
individuals, and the G20210A prothrombin polymorph-
ism was found in 13%. We found, however, no associa-
tion between the G20210A prothrombin polymorphism
and increased thromboembolic disease, despite the
unusually high prevalence in this kindred, including a
number of individuals with both protein C deficiency
and the G20210A polymorphism [10].
Since increased thrombin generation has been asso-
ciated with a higher prothrombin concentration in vivo
[11,12], we postulated a potential beneficial effect of
increased thrombomodulin-mediated activated protein
C generation in carriers of the prothrombin G20210A
mutation. This hypothesis was not supported in a small
preliminary study in which we correlated plasma con-
centrations of the protein C activation peptide, pro-
thrombin fragment 1 + 2 and fibrinopeptide A with
prothrombin concentration. We observed a positive
association of prothrombin concentrations with throm-
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bin generation (fragment 1 + 2) and thrombin activity
(fibrinopeptide A), but no association with protein C
activation peptide levels [11]. In the present study we
have further evaluated this hypothesis in a larger
sample of the family, by assessing the plasma concen-
tration of the complex of activated protein C combined
with protein C inhibitor (APC–PCI). Protein C inhibi-
tor is a molecular weight 57 000 serine protease inhibi-
tor with a plasma concentration of 90 nmol/l [13,14].
Plasma concentrations of APC–PCI in part reflect the
degree of activation of the protein C system. Previously
described assays for APC–PCI have not been sensitive
enough to accurately measure the full range of concen-
trations of the complex in healthy individuals. In this
study we have utilized a new and highly sensitive assay
for measuring the concentration of APC–PCI complex
as a measure of the level of activation of protein C [15].
Methods
Participants
Blood samples were collected from 201 family members
of a large French-Canadian kindred with type I protein
C deficiency, including spouses of family members who
have children. All samples were collected in 2002 into
sodium citrate pH 4.3 Stabilyte tubes (Biopool, Umeå,
Sweden). The ascertainment and evaluation of the
family members was previously described [3]. All sub-
jects completed questionnaires regarding general demo-
graphic information, current health status, current
medication, obstetric history, and personal history with
regard to events (venous as well as arterial thrombosis
and haemorrhages) and risk factors for venous thrombo-
sis (i.e. surgeries, hospital admissions, bed rest, plaster
cast). Completed forms were stored with only the
patient identifier codes to protect patient confidential-
ity. All participating subjects gave informed consent.
This study was approved by the Human Experimenta-
tion Committee of the University of Vermont College
of Medicine.
Six individuals using oral anticoagulants at the time of
the blood draw had levels of APC–PCI complex
ranging from 0.01 to 0.03 g/l. These individuals were
excluded from all calculations.
Laboratory methods
We measured protein C activity levels by performing a
clot-based functional assay using a kit provided by
Diagnostica Stago (Parsippany, New Jersey, USA) [16].
The inter-assay coefficient of variation of this assay was
5.5%. The presence of the 3363C insertion in the
protein C gene was determined by amplification of
genomic DNA using a mutagenic oligonucleotide pri-
mer that in concert with the inserted C mutation
creates a Bg1I cleavage site. The product was digested
with Bg1I and analysed on a 2% agarose gel [17]. The
prothrombin G20210A allele was detected by amplifica-
tion of genomic DNA with a mutagenic primer result-
ing in a HindIII cleavage site when the A-allele was
present [18].
Concentrations of the APC–PCI complex were meas-
ured by a previously described assay [15]. Samples were
incubated with monoclonal biotinylated capture anti-
body M36, which recognizes a conformation-dependent
neo-epitope in APC–PCI complexes [15,19]. The mean
level of APC–PCI complexes for a reference group,
consisting of Swedish healthy individuals (n ¼ 80; mean
age, 42 years; 20 men and 60 women), was 0.13 g/l
(range, 0.07–0.26 g/l) [20]. The functional detection
limit (intra-assay coefficient of variation , 20%) in
Stabilyte plasma is 32 ng/l (unpublished data).
Statistical methods
SPSS (SPSS Inc., Chicago, Illinois, USA) was used to
calculate the mean and 95% confidence intervals (CIs)
(mean  1.96 3 standard error) of the levels of the
APC–PCI complex. Correlation analysis for levels of
the APC–PCI complex and protein C activity was
performed by calculating Pearson’s correlation coeffi-
cient, and its non-parametric equivalent the Spearman’s
rank correlation coefficient. Pearson correlation coeffi-
cients were similar to the Spearman’s rank correlation
coefficients, but because the data were not normally
distributed only the latter are presented. For each
Spearman’s rank correlation coefficient, we calculated
the 95% CI [21]. Correlations were calculated without
accounting for the family structure. However, the
heritability of APC–PCI and protein C were both low
enough to perform analyses that do not account for
family structure [22].
Results
APC–PCI levels and information on carriership of the
prothrombin G20210A mutation were available for 55
family members with the protein C 3363C insertion
and 140 family members without this mutation (35
were spouses). Of these 195 individuals, 83 were men
(43%), 19 (10%) had experienced a venous thrombosis
in the past, and the prothrombin mutation was present
in 24 of the family members (12%). The mean age at
the blood draw was 41 years (range, 10–78 years).
Table 1 shows that family members with the protein C
mutation had lower plasma concentrations of APC–PCI
complex than individuals without the mutation. Protein
C activity levels correlated highly with APC–PCI
complex levels (n ¼ 195; rs ¼ 0.69; 95% CI, 0.61–0.76).
Figure 1 shows the scatterplot for the protein C activity
levels and the APC–PCI complex levels with the
exclusion of two subjects with APC–PCI complex
concentrations . 1 g/l. The exclusion of these two
individuals did not change the correlation coefficient
(n ¼ 193; rs ¼ 0.68; 95% CI, 0.59–0.75). The correlation
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was almost similar in family members with the protein
C 3363C insertion (n ¼ 55; rs ¼ 0.50; 95% CI, 0.26–
0.68) and family members without the protein C 3363C
insertion (n ¼ 140; rs ¼ 0.44; 95% CI, 0.29–0.57).
The levels of APC–PCI complex were not different
between carriers and non-carriers of the prothrombin
G20210A mutation (Table 1), those with or without a
history of venous thrombosis, or between men and
women (data not shown).
Discussion
The prothrombin G20210A variant is clearly associated
with an increased risk for venous thromboembolic
disease [18,23–25], as are the higher plasma levels of
prothrombin associated with the A-allele [8,18,26,27].
Thrombin generation, as reflected by prothrombin
fragment 1 + 2 plasma concentration, varies directly
with prothrombin concentration [11,12]. This latter
observation fits well with the increased risk of thrombo-
sis associated with the mutation and raises questions
with respect to the finding that the mutation does not
confer risk in the presence of protein C deficiency in
this French-Canadian family [11]. However, the find-
ings of the present study do not support our hypothesis
of increased protein C activation resulting from higher
prothrombin concentrations associated with the pro-
thrombin G20210A polymorphism. It is possible that
the plasma concentration of APC–PCI does not reflect
APC production, but the positive correlation between
plasma protein C levels and APC–PCI does not support
this explanation. The only described situation in which
APC–PCI does not reflect APC production is when
PCI has been depleted, such as in seriously ill septic or
DIC patients [28]. Thus, our findings suggest that if
the observed higher levels of thrombin generation and
activity compensate for the impaired protein C pathway
in this thrombophilic family, it must be by an alter-
native mechanism.
Thrombin plays multiple roles in coagulation, fibrinoly-
sis, platelet activation, cell growth, peripheral blood cell
activation, anticoagulation, vascular endothelium and
cell migration. Thus, the interaction of the prothrombin
G20210A polymorphism with protein C deficiency in
this thrombophilic kindred may not directly involve the
protein C system. A recently described thrombin-
mediated endothelial cell-dependent mechanism for
FVa inactivation is a possible alternative mechanism
[29]. However, as is the case with this multifunctional
protein, thrombin has also been shown to inhibit the
inactivation of FVa by activated protein C in purified
systems [30]. Thus, we are left with an apparently
paradoxical interaction of two well-established risk
factors and an opportunity to learn more about the tonic
thrombohaemorrhagic balance first postulated by Åstrup
in 1958 [31].
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Table 1 Activated protein C and protein C inhibitor (APC–PCI) complex levels
(g/l) of the family members
APC-PCI complex
n Mean (95% confidence interval) Range
Protein C 3363C insertion 55 0.08 (0.07–0.09) 0.01–0.17
+ PT G20210A 11 0.08 (0.07–0.10) 0.03–0.13
– PT G20210A 44 0.08 (0.07–0.09) 0.01–0.17
No protein C 3363C insertion 140 0.18 (0.15–0.21) 0.07–2.20
+ PT G20210A 13 0.19 (0.14–0.23) 0.10–0.37
– PT G20210A 127 0.18 (0.14–0.24) 0.07–2.20
PT, prothrombin.






















Scatterplot of activated protein C and protein C inhibitor (APC–PCI)
complex levels and protein C activity levels for 193 family members
with or without the protein C 3363C mutation (excluding two
individuals with APC-PCI complex levels above 1 g/l).
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